Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

Key facts

Sponsor

University of Oxford

Principal Investigator

Adrian VS Hill, Prof

Jenner Institute

Intervention

ChAdOx1 RVF(biological)

Enrollment

15 enrolled

Eligibility

18-50 years · All sexes

Timeline

2021 – 2022

Study locations (1)

• CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Coccidioidomycosis

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT06799234
  Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)
  University of Oxford
• ACTIVE NOT RECRUITINGPHASE1NCT06925919
  Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
  IDBiologics, Inc.
• ACTIVE NOT RECRUITINGNANCT06913803
  To Find Effectiveness of Stretching Versus Soft Tissue Mobilization in Coccydynia in Postpartum Females
  Superior University
• RECRUITINGPHASE2NCT03609398
  Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
  U.S. Army Medical Research and Development Command
• RECRUITINGNCT02190266
  Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
  National Institute of Allergy and Infectious Diseases (NIAID)

See all trials for Coccidioidomycosis →